What question did this study set out to answer?

January 20, 20263 citations

An FDA analysis of the association of tumor growth rate, overall survival and progression-free survival in patients with metastatic NSCLC.

JMJustin N. Malinou JFJiaxin Fan JCJoyce Cheng

Key Points

The study aims to evaluate the relationship between tumor growth rate, overall survival, and progression-free survival in metastatic non-small cell lung cancer (NSCLC).
Conducted an analysis of tumor growth rates in patients with metastatic NSCLC.
Assessed the association of growth rate (g value) with overall survival (OS) and progression-free survival (PFS).
Identified the need for prospective studies and meta-analyses for further validation.
Found a potential association between g value and long-term outcomes such as OS and PFS.
Indicated that understanding growth rates may help in determining effective therapies for drug development.

Abstract

Characterization of the growth rate may provide additional information regarding the potential clinical activity of a drug, which could aid in the selection of therapies for further drug development. While the g value has the potential to provide an early assessment of new therapies in a clinical trial before a time-to-event endpoint is reached, further evaluation through prospective studies and meta-analyses is needed to assess the association of g value with long-term outcomes, such as PFS and OS.

Ask AI

Helpful

Bookmark

View Full Paper